



SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50546/002002
	Serial No.	10/514,304
	Applicant	Beliveau
	Filing Date	July 1, 2005
	Group	1615
	IDS Filed	October 9, 2008
	Customer No.	21559

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant
	4,671,958	06/09/1987	Rodwell et al.
	4,801,575	01/31/1989	Pardridge
	4,902,505	02/20/1990	Pardridge et al.
	4,942,184	07/17/1990	Haugwitz et al.
	5,028,697	07/02/1991	Johnson et al.
	5,578,451	11/26/1996	Nishimoto
	5,627,270	05/06/1997	Kahne et al.
	5,683,694	11/04/1997	Bagshawe et al.
	5,948,888	09/07/1999	de la Monte et al.
	5,955,444	09/21/1999	Ingram et al.
	5,962,266	10/05/1999	White et al.
	5,981,564	11/09/1999	Pagé et al.
	6,093,692	07/25/2000	Shen et al.
	6,245,359	06/12/2001	Milstein et al.
	6,348,207	02/19/2002	Milstein et al.
	6,376,648	04/23/2002	White et al.
	6,475,781	11/05/2002	Mercola et al.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50546/002002
	Serial No.	10/514,304
	Applicant	Beliveau
	Filing Date	July 1, 2005
	Group	1615
	IDS Filed	October 9, 2008
	Customer No.	21559

U.S. PATENT DOCUMENTS			
	6,475,481	11/05/2002	Talmadge
	6,495,513	12/17/2002	Rueger et al.
	6,613,890	09/02/2003	White et al.
	6,906,033	06/14/2005	White et al.
	7,019,123	03/28/2006	Tamburini et al.
	7,049,058	05/23/2006	Singh
	7,115,707	10/03/2006	Ben-Sasson et al.
	2003/0129186	07/10/2003	Beliveau et al.
	2004/0077540	04/22/2004	Quay
	2005/0042227	02/24/2005	Zankel et al.
	2005/0058702	03/17/2005	Ben-Sasson et al.
	2005/0100986	05/12/2005	Verma et al.
	2005/0178395	08/18/2005	Hunter et al.
	2005/0183731	08/25/2005	Hunter et al.
	2006/0251713	11/09/2006	Ben-Sasson et al.

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50546/002002
	Serial No.	10/514,304
	Applicant	Beliveau
	Filing Date	July 1, 2005
	Group	1615
	IDS Filed	October 9, 2008
	Customer No.	21559

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
	CA 2283474	09/11/1998	Canada	
	CA 2525236	01/13/2005	Canada	
	DE 199 53 696	05/10/2001	Cherkasky	No
	WO 87/05702	09/24/1987	Robertson et al.	
	WO 02/33090	04/25/2002	Garde et al.	
	WO 03/009815	02/06/2003	Beliveau et al.	
	WO 04/060403 A3	07/22/2004	Beliveau et al.	
	WO 06/086870	08/24/2006	Beliveau et al.	
	WO 07/009229	01/25/2007	Beliveau et al.	

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Ballabh et al., "The Blood-Brain Barrier: An Overview Structure, Regulation, and Clinical Implications" <i>Neurobiology of Disease</i> 16:1-13 (2004).
	Bickel et al., "Delivery of Peptides and Proteins Through the Blood-Brain Barrier" <i>Advanced Drug Delivery Reviews</i> 46:247-279 (2001).
	Bork et al., "Go Hunting in Sequence Databases But Watch Out for the Traps" <i>Trends in Genetics</i> 12:425-427 (1996).
	Bork, "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle" <i>Genome Research</i> 10:398-400 (2000).
	Brenner, "Errors in Genome Annotation" <i>Trends in Genetics</i> 15:132-133 (1999).
	Deane et al., "LRP/Amyloid β -Peptide Interaction Mediates Differential Brain Efflux of A β Isoforms" <i>Neuron</i> 43:333-344 (2004).
	Dehouck et al., "A New Function for the LDL Receptor: Transcytosis of LDL Across the Blood-Brain Barrier" <i>The Journal of Cell Biology</i> 138:877-889 (1997).
	Dehouck et al., "Drug Transfer Across the Blood-Brain Barrier: Correlation Between In Vitro and In Vivo Models" <i>Journal of Neurochemistry</i> 58:1790-1797 (1992).
EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50546/002002
	Serial No.	10/514,304
	Applicant	Beliveau
	Filing Date	July 1, 2005
	Group	1615
	IDS Filed	October 9, 2008
	Customer No.	21559

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Demeule et al., "High Transcytosis of Melanotransferrin (P97) Across the Blood-Brain Barrier" <i>Journal of Neurochemistry</i> 83:924-933 (2002).
	Demeule et al., "Isolation of Endothelial Cells from Brain, Lung, and Kidney: Expression of the Multidrug Resistance P-Glycoprotein Isoforms" <i>Biochemical and Biophysical Research Communications</i> 281:827-834 (2001).
	Doerks et al., "Protein Annotation: Detective Work for Function Prediction" <i>Trends in Genetics</i> 14:248-250 (1998).
	Fillebeen et al., "Receptor-Mediated Transcytosis of Lactoferrin Through the Blood-Brain Barrier" <i>The Journal of Biological Chemistry</i> 274:7011-7017 (1999).
	Fromm, "P-Glycoprotein: A Defense Mechanism Limiting Oral Bioavailability and CNS Accumulation of Drugs" <i>International Journal of Clinical Pharmacology and Therapeutics</i> 38:69-74 (2000).
	Grabb et al., "Neoplastic and Pharmacological Influence on the Permeability of an in vitro Blood-Brain Barrier" <i>Journal of Neurosurgery</i> 82:1053-1058 (1995).
	Guillot et al., "Angiotensin Peptide Regulation of Bovine Brain Microvessel Endothelial Cell Monolayer Permeability" <i>Journal of Cardiovascular Pharmacology</i> 18:212-218 (1991).
	Gumbleton et al., "Progress and Limitations in the Use of In Vitro Cell Cultures to Serve as a Permeability Screen for the Blood-Brain Barrier" <i>Journal of Pharmaceutical Sciences</i> 90:1681-1698 (2001).
	Hawkins et al., "The Blood-Brain Barrier/Neurovascular Unit in Health and Disease" <i>Pharmacological Reviews</i> 57:173-185 (2005).
	Hussain et al., "The Mammalian Low-Density Lipoprotein Receptor Family" <i>Annual Review of Nutrition</i> 19:141-172 (1999).
	Ito et al., "Functional Characterization of the Brain-to-Blood Efflux Clearance of Human Amyloid- β Peptide (1-40) Across the Rat Blood-Brain Barrier" <i>Neuroscience Research</i> 56:246-252 (2006).
	Kiernan et al., "Fluorescent-Labelled Aprotinin: A New Reagent for the Histochemical Detection of Acid Mucosubstances" <i>Histochemie</i> 34:77-84 (1973).
	Kobayashi et al., "The Protease Inhibitor Bikunin, a Novel Anti-Metastatic Agent" <i>Biol. Chem.</i> 384:749-754 (2003).
	Koo et al., "Differential Expression of Amyloid Precursor Protein mRNAs in Cases of Alzheimer's Disease and in Aged Nonhuman Primates" <i>Neuron</i> 2:97-104 (1990).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50546/002002
	Serial No.	10/514,304
	Applicant	Beliveau
	Filing Date	July 1, 2005
	Group	1615
	IDS Filed	October 9, 2008
	Customer No.	21559

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Kreuter et al., "Apolipoprotein-Mediated Transport of Nanoparticle-Bound Drugs Across the Blood-Brain Barrier" <i>Journal of Drug Targeting</i> 10:317-325 (2002).
	Lai et al., "The Critical Component to Establish in vitro BBB Model: Pericyte" <i>Brain Research Reviews</i> 50:258-265 (2005).
	Larionova et al., "Carbohydrate-Containing Derivatives of the Trypsin-Kallikrein Inhibitor Aprotinin from Bovine Organs" <i>Biol. Chem. Hoppe-Seyler</i> 366:743-748 (1985).
	Larsson, "Megalin, an Endocytotic Receptor With Signalling Potential" <i>Acta Universitatis Upsaliensis Uppsala</i> 1-60 (2006).
	Ma et al., "Cationic Charge-Dependent Hepatic Delivery of Amidated Serum Albumin" <i>Journal of Controlled Release</i> 102:583-594 (2005).
	Marinò et al., "Megalin-Mediated Transcytosis of Thyroglobulin by Thyroid Cells is a Calmodulin-Dependent Process" <i>Thyroid</i> 10:461-469 (2000).
	Marinò et al., "Transcytosis of Retinol-Binding Protein Across Renal Proximal Tubule Cells After Megalin (gp 330)-Mediated Endocytosis" <i>The Journal of the American Society of Nephrology</i> 12:637-648 (2001).
	Martel et al., "Transport of Apolipoproteins E and J at the Blood-Brain Barrier Relevance to Alzheimer's Disease" <i>S.T.P. Pharma Sciences</i> 7:28-36 (1997).
	McCarty, "Cell Biology of the Neurovascular Unit: Implications for Drug Delivery Across the Blood-Brain Barrier" <i>ASSAY and Drug Development Technologies</i> 3:89-95 (2005).
	Ngo et al., "Computational Complexity: Protein Structure Prediction, and the Levinthal Paradox" <i>The Protein Folding Problem and Tertiary Structure Prediction</i> 491-495 (1994).
	Orlando et al., "Identification of the Second Cluster of Ligand-Binding Repeats in Megalin as a Site for Receptor-Ligand Interactions" <i>Proceedings of The National Academy of Sciences</i> 94:2368-2373 (1997).
	Pan et al., "Efficient Transfer of Receptor-Associated Protein (RAP) Across the Blood-Brain Barrier" <i>Journal of Cell Science</i> 117:5071-5078 (2004).
	Pardridge "Blood-Brain Barrier Biology and Methodology" <i>Journal of NeuroVirology</i> 5:556-569 (1999).
	Pardridge "CNS Drug Design Based on Principles of Blood-Brain Barrier Transport" <i>Journal of Neurochemistry</i> 70:1781-1792 (1998).
	Prince et al., "Lipoprotein Receptor Binding, Cellular Uptake, and Lysosomal Delivery of Fusions Between the Receptor-Associated protein (RAP) and α -L-Iduronidase or Acid α -Glucosidase" <i>The Journal of Biological Chemistry</i> 279:35037-35046 (2004).
EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50546/002002
	Serial No.	10/514,304
	Applicant	Beliveau
	Filing Date	July 1, 2005
	Group	1615
	IDS Filed	October 9, 2008
	Customer No.	21559

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Ramakrishnan, "The Role of P-Glycoprotein in the Blood-Brain Barrier" <i>The Einstein Quarterly Journal of Biology and Medicine</i> 19:160-165 (2003).
	Régina et al., "Differences in Multidrug Resistance Phenotype and Matrix Metalloproteinases Activity Between Endothelial Cells from Normal Brain and Glioma" <i>Journal of Neurochemistry</i> 84:316-324 (2003).
	Schermann, "Drug Delivery to Brain Via the Blood-Brain Barrier" <i>Vascular Pharmacology</i> 38:349-354 (2002).
	Schinkel, "P-Glycoprotein, a Gatekeeper in the Blood-Brain Barrier" <i>Advanced Drug Delivery Reviews</i> 36:179-194 (1999).
	Seidel et al., "Effects of Trasylol on the Blood-Brain Barrier in Rats" <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> Springer, Berlin, DE 284: Pg. R73 (1974).
	Shibata et al., "Clearance of Alzheimer's Amyloid- β_{1-40} Peptide From Brain LDL Receptor-Related Protein-1 at the Blood-Brain Barrier" <i>The Journal of Clinical Investigation</i> 106:1489-1499 (2000).
	Shiiki et al., "Brain Insulin Impairs Amyloid- β (1-40) Clearance From the Brain" <i>The Journal of Neuroscience</i> 24:9632-9637 (2004).
	Shimura et al., "Transport Mechanism of a New Behaviorally Highly Potent Adrenocorticotrophic Hormone (ACTH) Analog, Ebiratide, Through the Blood-Brain Barrier" <i>The Journal of Pharmacology and Experimental Therapeutics</i> 258:459-465 (1991).
	Skolnick et al., "From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era" <i>Trends in Biotech</i> 18:34-39 (2000).
	Smith, "Brain Perfusion Systems for Studies of Drug Uptake and Metabolism in the Central Nervous System" <i>Models for Assessing Drug Absorption and Metabolism</i> 285-307 (1996).
	Smith et al., "The Challenges of Genome Sequence Annotation or 'The Devil is in the Details'" <i>Nature Biotechnology</i> 15:1222-1223 (1997).
	Tamai et al., "Structure-Internalization Relationship for Absorptive-Mediated Endocytosis of Basic Peptides at the Blood-Brain Barrier" <i>The Journal of Pharmacology and Experimental Therapeutics</i> 280:410-415 (1997).
	Temsamani et al., "Vector-Mediated Drug Delivery to the Brain" <i>Expert Opinion on Biological Therapy</i> 1:773-782 (2001).
	Terasaki et al., "New Approaches to in vitro Models of Blood-Brain Barrier Drug Transport" <i>Drug Discovery Today</i> 8:944-954 (2003).
	Triguero et al., "Capillary Depletion Method for Quantification of Blood-Brain Barrier Transport of Circulating Peptides and Plasma Proteins" <i>Journal of Neurochemistry</i> 54:1882-1888 (1990).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50546/002002
	Serial No.	10/514,304
	Applicant	Beliveau
	Filing Date	July 1, 2005
	Group	1615
	IDS Filed	October 9, 2008
	Customer No.	21559

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Wells, "Additivity of Mutational Effects in Proteins" <i>Biochemistry</i> 29:8509-8517 (1990).
	Witt et al., "Peptide Drug Modifications to Enhance Bioavailability and Blood-Brain Barrier Permeability" <i>Peptides</i> 22:2329-2343 (2001).
	Yepes et al., "Tissue-Type Plasminogen Activator Induces Opening of the Blood-Brain Barrier Via the LDL Receptor-Related Protein" <i>The Journal of Clinical Investigation</i> 112:1533-1540 (2003).
	Zlokovic et al., "Glycoprotein 330/Megalin: Probable Role in Receptor-mediated Transport of Apolipoprotein J Alone and in a Complex With Alzheimer Disease Amyloid β at the Blood-Brain and Blood Cerebrospinal Fluid Barriers" <i>Proceedings of The National Academy of Sciences USA</i> 93:4229-4234 (1996).
	European Patent Office Communication Containing Extended Search Report of Application Number 05770546.9-1212 / 1859041, Dated September 8, 2008.
	European Patent Office Communication Containing European Search Report of Application Number 04700102.9 Dated January 26, 2007.
	International Preliminary Report on Patentability of International Patent Application No. PCT/CA2004/000011 dated June 1, 2005.
	International Search Report of International Application No. PCT/CA2006/001165 dated November 9, 2006.
	Office Action pertaining to U.S. Patent Application No.: 11/185,947 mailed March 27, 2007.
	Office Action pertaining to U.S. Patent Application No.: 11/185,947 mailed March 7, 2008.
	Written Opinion of the International Searching Authority of International Application No. PCT/CA2004/000011 mailed on June 1, 2005.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	